NCT01543724 is a Phase 4 clinical trial of Lithium in Bipolar Disorder, sponsored by Ewha Womans University.

Who is sponsoring NCT01543724?

NCT01543724 is sponsored by Ewha Womans University.

What drugs are being tested in NCT01543724?

Interventions in NCT01543724: Lithium.

What condition does NCT01543724 study?

NCT01543724 studies Bipolar Disorder.

Is NCT01543724 still recruiting?

NCT01543724 is currently withdrawn. Last updated 9 February 2018.

Last reviewed 2018-02-09 · How we verify

NCT01543724

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder

Withdrawn Phase 4 Last updated 9 February 2018

What this trial tests

Phase 4 trial testing Lithium in Bipolar Disorder. Withdrawn.

Timeline

1 June 2015

Primary endpoint
31 December 2017

31 December 2017

Quick facts

Lead sponsor	Ewha Womans University
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Start date	1 June 2015
Primary completion	31 December 2017
Estimated completion	31 December 2017
Sites	1 location across South Korea

Drugs / interventions tested

Lithium

Conditions studied

Bipolar Disorder — all drugs for Bipolar Disorder →

Sponsor

Ewha Womans University

Who can join

Adults 19 to 55, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will assess Li-induced gray matter volume changes with regard to the endophenotype of GSK3beta polymorphism. The changes of gray matter are supposed to be more attributable to neurotrophic and neuroprotective characteristics of Li, which were closely related to the inhibition of apoptotic activity of GSK3beta.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

GSK-3 as potential target for therapeutic intervention in cancer.
McCubrey JA, Steelman LS, Bertrand FE, Davis NM, et al · · 2014 · cited 383× · PMID 24931005 · DOI 10.18632/oncotarget.2037
A partnership with the proteasome; the destructive nature of GSK3.
Robertson H, Hayes JD, Sutherland C. · · 2018 · cited 74× · PMID 29102676 · DOI 10.1016/j.bcp.2017.10.016
Use of functional imaging across clinical phases in CNS drug development.
Borsook D, Becerra L, Fava M. · · 2013 · cited 46× · PMID 23860483 · DOI 10.1038/tp.2013.43

Verify or expand the search:

Other trials of Lithium

Trials testing the same drug.

NCT06929273 — A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) · Phase 3 · recruiting
NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT05973786 — The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in · Phase 3 · recruiting
NCT06729970 — A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects · Phase 1 · completed
NCT06051240 — Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy · Phase 2 · recruiting

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT06911931 — Visual Perception in Schizophrenia · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07479758 — Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Out · recruiting
NCT07140913 — A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur · Phase 3 · recruiting

Other Ewha Womans University trials

Trials by the same sponsor.

NCT06426342 — Development and Feasibility of a Metaverse-based Blended Online Intervention to Prevent Employees' Depression · NA · completed
NCT07483892 — Effects of Cervical Sensorimotor Training With Pilates Reformer on Balance and Cervical Joint Position Sense · NA · completed
NCT03357653 — Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 · Phase 3 · unknown
NCT03337789 — Efficacy of Polygonatum Sibiricum on Sleep Quality Improvement · NA · completed
NCT01543139 — Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression · Phase 2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01543724 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ewha Womans University
Last refreshed: 9 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01543724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing